Biotech Glycomine Closes $115M Series C Funding Round
Biotechnology company Glycomine Inc. on Wednesday announced that it wrapped its Series C funding round with $115 million in tow to advance its lead candidate into a Phase 2b clinical trial....To view the full article, register now.
Already a subscriber? Click here to view full article